Personalis, Inc. (PSNL)

NASDAQ: PSNL · IEX Real-Time Price · USD
4.45
0.34 (8.27%)
May 27, 2022 11:37 AM EDT - Market open
Market Cap202.24M
Revenue (ttm)79.84M
Net Income (ttm)-81.03M
Shares Out45.45M
EPS (ttm)-1.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume239,824
Open4.13
Previous Close4.11
Day's Range4.09 - 4.47
52-Week Range3.94 - 28.47
Beta1.71
AnalystsBuy
Price Target20.40 (+358.4%)
Earnings DateMay 4, 2022

About PSNL

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT D...

IndustryLife Sciences Tools & Services
IPO DateJun 20, 2019
CEOJohn West
Employees325
Stock ExchangeNASDAQ
Ticker SymbolPSNL
Full Company Profile

Financial Performance

In 2021, Personalis's revenue was $85.49 million, an increase of 8.70% compared to the previous year's $78.65 million. Losses were -$65.23 million, 58.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for PSNL stock is "Buy." The 12-month stock price forecast is 20.4, which is an increase of 358.43% from the latest price.

Price Target
$20.4
(358.43% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of -10.53% and 2.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Personalis Reports First Quarter 2022 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2022. F...

3 weeks ago - Business Wire

Personalis to Present at Upcoming Investor Conferences

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the following investor conference...

4 weeks ago - Business Wire

Evaxion to Utilize Personalis' ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Mel...

MENLO PARK, Calif. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis' ImmunoID NeXT Platform in...

Other symbols:EVAX
1 month ago - Business Wire

Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the appointment of James Azzaro to the newly created position ...

1 month ago - Business Wire

Personalis to Announce First Quarter 2022 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2022 financial results on Wednesday...

1 month ago - Business Wire

Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of its study titled, "A machine learning algor...

1 month ago - Business Wire

Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced the issuance of a key US Patent related to its industry-leading minimal residual...

1 month ago - Business Wire

Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Ann...

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced its co-authorship of a study with Merck KGaA, Darmstadt, Germany, a ...

1 month ago - Business Wire

Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 21st Annual Needham Virtual H...

1 month ago - Business Wire

Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors

MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that Karin Eastham has been appointed as Persona...

2 months ago - Business Wire

Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced it is presenting new data in scientific posters at the American Asso...

2 months ago - Business Wire

Personalis (PSNL) Reports Q4 Loss, Lags Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 11.76% and 0.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Personalis Reports Fourth Quarter and Full Year 2021 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended De...

3 months ago - Business Wire

Personalis to Present at the Cowen 42nd Annual Health Care Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Cowen 42nd Annual Health Care...

3 months ago - Business Wire

Earnings Preview: Personalis (PSNL) Q4 Earnings Expected to Decline

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research i...

MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research

3 months ago - Business Wire

Personalis to Announce Fourth Quarter and Full-Year Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full-year 2021 financial resul...

3 months ago - Business Wire

Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG MedTech, Digital Health,...

3 months ago - Business Wire

Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported unaudited preliminary revenue for the fourth quar...

4 months ago - Business Wire

Personalis to Participate in the 24th Annual Needham Virtual Growth Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 24th Annual Needham Virtual Gr...

4 months ago - Business Wire

Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-P...

MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity

5 months ago - Business Wire

Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 33rd Annual Piper Sandler Virt...

6 months ago - Business Wire

Personalis Named to Inc.'s 2021 Best-Led Companies List

MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis Named to Inc.'s 2021 Best-Led Companies List

6 months ago - Business Wire

Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

6 months ago - Business Wire